Sage TherapeuticsSAGE
13F holders, Q3 2025 (September 30)5holders −187
0new positions
186sold out
$8.76avg. 13F price*
At the end of Q3 2025, 5 institutions reported holding Sage Therapeutics Inc. (SAGE) in their 13F filings, down 187 from Q2 2025. 0 opened new positions and 186 sold out. The largest holders were DekaBank Deutsche Girozentrale ($455K), Osaic Holdings, Inc. ($35K) and IFP Advisors, Inc ($4K).
- Company
- Sage Therapeutics Inc.
- CUSIP
- 78667J108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 186 | $445.2M |
All 13F filers, Q2 2025 → Q3 2025: 16,625 shares bought and 48,818,104 shares sold, net −48,801,479 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| DekaBank Deutsche Girozentrale | 0.00% | No change | 22,220 | $455K |
| Osaic Holdings, Inc. | 0.00% | Reduce -3.3% | 4,045 | $35K |
| IFP Advisors, Inc | 0.00% | Add +1.1% | 445 | $4K |
| Huntington National Bank | 0.00% | No change | 1 | $9 |
| XTX Topco Ltd | 0.00% | Add +127.1% | 29,698 | $0 |
"% of holder's portfolio" is SAGE's weight in each manager's 13F, not the share of Sage Therapeutics Inc. the manager owns.